Induction of systemic, mucosal, and cellular immunity against SARS‐CoV‐2 in mice vaccinated by trans‐airway with a S1 protein combined with a pulmonary surfactant‐derived adjuvant SF‐10

BACKGROUND: There is a need for vaccines that can induce effective systemic, respiratory mucosal, and cellular immunity to control the COVID‐19 pandemic. We reported previously that a synthetic mucosal adjuvant SF‐10 derived from human pulmonary surfactant works as an efficient antigen delivery vehi...

Descripción completa

Detalles Bibliográficos
Autores principales: Kimoto, Takashi, Sakai, Satoko, Kameda, Keiko, Morita, Ryoko, Takahashi, Etsuhisa, Shinohara, Yasuo, Kido, Hiroshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9996429/
https://www.ncbi.nlm.nih.gov/pubmed/36909295
http://dx.doi.org/10.1111/irv.13119

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9996429/
https://www.ncbi.nlm.nih.gov/pubmed/36909295
http://dx.doi.org/10.1111/irv.13119

Ejemplares similares